Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: KHS who wrote (21661)	5/5/1999 5:59:00 PM
From: wvalx	Read Replies (2) \| Respond to of 23519

<<Keeping rating as a buy with a 12 month price target of $9>> I hate to sound greedy, but with the apparent worst behind Vivus and so much potential for good news in Alibra/femme cream/PE/MUSE sales, $9 for a 12 month target sounds a little weak. If everything works out this year (the domestic partner for MUSE/Alibra being the single biggest news event), I would think $9 would be a distant memory. Then again, Charlie has been burned before and maybe is being a wee bit more cautious.